Mayne Pharma presentation for JMP Life Sciences Conference
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA TO PRESENT AT JMP SECURITIES LIFE
SCIENCES CONFERENCE ON 15 MAY 2023 IN NEW YORK CITY
15 May 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced that
Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the JMP Securities
Life Sciences Conference as follows:
Date:
Time:
Location:
Monday, May 15, 2023
12:30pm US Eastern time
New York Hilton Midtown, 1335 Avenue of the Americas, New York, NY
A copy of the presentation slides is attached.
Management will also be available for one-on-one meetings.
For further information contact:
Australia:
Craig Haskins
+61 421 029 843
ir@maynepharma.com
US:
Lisa M. Wilson
+917 543 9932
ir@maynepharma.com
Authorised for release to the ASX by the Chair.
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising
novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma
also provides contract development and manufacturing services to clients worldwide. Mayne
Pharma has a 40- year track record of innovation and success in developing new oral drug delivery
systems. These technologies have been successfully commercialised in numerous products that
continue to be marketed around the world. To learn more about Mayne Pharma, please visit
maynepharma.com.
Mayne Pharma
Group Limited
JMP Securities Life Sciences Conference
May 15, 2023
Shawn Patrick O’Brien, CEO
Aaron Gray, CFO
Disclaimer
The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited
Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors.
Non-IFRS information
● Other than as indicated, the financial information contained in this document is directly extracted or calculated from the audited Financial Statements.
Throughout this document some non-IFRS financial information is stated, excluding certain specified income and expenses. Results excluding such items
are considered by the Directors to provide a meaningful basis for comparison from period to period.
● Earnings before interest, tax, depreciation and amortisation (EBITDA) – a non-IFRS term – is considered by Directors to be a meaningful measure of the
operating earnings and performance of the Group and this information may be useful for investors.
● The non-IFRS financial information has not been audited by the Group’s auditors.
Forward looking statements
● This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and
contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as
‘potential’, ‘expect’, ‘anticipate’, ‘intend’, ‘plan’ and ‘may’, and other words of similar meaning. No representation, warranty or assurance (express or
implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially
from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are
cautioned not to place undue reliance on such forward looking statements. Subject to the Company’s continuous disclosure obligations at law and under
the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The
factors that may affect the Company’s future performance include, among others: changes in economic conditions, changes in the legal and regulatory
regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities, changes in behaviour of major
customers, suppliers and competitors, interruptions to manufacturing or distribution, the success of research and development activities and research
collaborations and the Company’s ability to protect its intellectual property.
Other
● A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed at maynepharma.com/investorrelations/results-reports and product descriptions are detailed at maynepharma.com/us-products and maynepharma.com/au-products.
● ANNOVERA®, ABSORICA®, ACTIKERALL®, ACZONE®, BIJUVA®, EPIDUO® FORTE, IMVEXXY®, NEXTSTELLIS®, ORACEA® and VITAMED® are trademarks of third
parties.
2
A lot of change over the last 7+ months
A period of significant structural change to reset Mayne Pharma for profitable growth
Key Observations, Actions And Priorities
People, products, and processes focused on the needs of patients to drive growth
● Organisational realignment began with a new US focused leadership team
driven to create commercial and operational excellence
● PEOPLE: new leadership team and aligning the culture to drive the best
outcomes for our patients, partners, and shareholders
● PROCESS: reduce complexity and right size our cost structure; ensure
visibility, transparency, and accountability in our sales, commercial and
operational performance
● PRODUCTS: focus on US women’s health and dermatology and
maximising the potential of International; capitalize on operating and
financial leverage through scale in the markets we serve
Patients
Process
● PATIENTS: deliver market leading products in US women’s health and
dermatology while satisfying the profitability needs of our business
● Deliver PROFITABLE GROWTH and strong free cash flow to rebuild value
for our shareholders
PROFITABLE GROWTH
4
Successful Execution of Strategy
GOAL: Become a more focused business with significant growth opportunities
Sale of
Metrics
Contract
Service
Sale of US
Retail
Generics to
DRL
➢ Commercialization
rights for TXMD’S
women’s health assets
➢ $140MM up front
➢ 3.8x EBITDA
➢ $475MM
➢ 16.5x EBITDA
Oct
2022
Capital Management Plan
Invested in
US Women’s
Health
Nov
2022
Dec
2022
Jan
2023
MAYNE PHARMA BECOMES ONE
OF THE LEADERS IN WOMEN’S
HEALTHCARE IN THE U.S.
➢ $90MM up front +
$15MM in milestone
payments
Feb
2023
Mar
2023
Apr
2023
➢ Repayment of A$358.7m
syndicated debt facilities
➢ Paid A$47.3m special dividend in
January 2023
➢ Ongoing discussions for new
corporate debt and working capital
facilities
➢ Winding down receivables-based
revolver
➢ Current cash position of A$239m
➢ Net cash position of A$135.8m
(cash less Rubric Convertible note,
current balance of Receivables
financing facility)
➢ Announced on market share buyback up to 10% of issued capital
5
Group Financial Overview
A$million1
1H23
1H22
1H23 v 1H22
Reported Revenue
101.2
150.4
(33%)
Reported Gross Profit
7.9
64.6
(88%)
Reported EBITDA
(99.2)
66.1
(250%)
Reported Net Loss After Tax
(129.2)
(208.4)
(38%)
Underlying EBITDA2
(53.1)
63.5
(184%)
Underlying EBITDA (excl. NEXTSTELLIS®)3
(25.9)
72.2
(136%)
●
Financial results are presented from continuing operations to exclude MCS which was disposed of on 4 October 2022
●
Group Revenue down largely as a result of decline in Portfolio Products Division (PPD) where sales declined in retail generics as a result of continued competition , and a
decline in revenue in certain products in the dermatology business as the normalisation of inventories in the distribution channel impacted sales for much of the half
●
Reported Gross Profit and EBITDA affected by foreign exchange losses on hedges placed against receipt of MCS proceeds
●
Reported net loss after tax driven by deferred tax asset write-downs and intangible asset impairments
1. Attributable to members. EBITDA excludes asset impairments.
2. Refer to FY22 Results Presentation for adjustments to underlying EBITDA
3. Excludes NEXTSTELLIS® direct contribution (gross profit less direct marketing / set up costs)
6
Group Financial Overview
1HFY23
Revenue
2HFY22
Revenue
1HFY22
Revenue
$26.8
$27.6
$28.6
$6.3
Portfolio Products
$4.2
Branded Products
$59.1
International/Other
$13.4
$125.6
Retail
Generics:
$48.0MM
Retail
Generics:
$75.5MM
$118.6
Retail
Generics:
$76.9MM
7
Branded Products Division (BPD)
Branded Products Division (BPD)
NEXTSTELLIS®
● NEXTSTELLIS® revenues were US$7.1m
- Up 123% on 2HFY22 (US$3.2m)
- Up 567% on 1HFY22 (US$1.1m)
● NEXTSTELLIS® direct operating expenses were US$23.9m
- Up 23% on 2HFY22
- Up 53% 1HFY22
TOLSURA® (SUBA®-itraconazole) and SOLTAMOX® (tamoxifen)
A$million
1H23
2H22
1H22
Reported revenue
13.4
6.3
4.2
Reported Gross Profit
10.7
5.1
3.3
Gross Profit %
80%
81%
79%
Direct operating
expense1
36.2
29.1
25.7
Direct contribution
(25.5)
(24.0)
(22.5)
Branded Products revenue by type (US$m)
● TOLSURA® and SOLTAMOX® revenues of $1.9m increased
35% on 2HFY22
7%
14%
US$9m
1. Direct marketing and NEXTSTELLIS® set up costs
79%
9
Women’s Health Acquisition: Accelerating Our Vision to Become a Leader
Prenatal Vitamins
CONTRACEPTION
PRENATAL
CARE
REPRODUCTIVE HEALTH
CONTRACEPTION/
FAMILY PLANNING PERIMENOPAUSE
VASOMOTOR
SYMPTOMS
DYSPAREUNIA
(Vulvar & Vaginal
Atrophy)
MENOPAUSE MANAGEMENT
10
Building a leading US Women’s Health Business (BPD)
Acquired Portfolio
Prenatal Vitamins
REPRODUCTIVE HEALTH
PRENATAL
MENOPAUSE MANAGEMENT
STRATEGIC PRIORITIES
✓ Successfully implement new commercial strategy for NEXTSTELLIS® to accelerate growth
in the US and Australia
✓ Deliver on the full Women’s Health franchise
✓ Improve margins and provide better patient access
✓ Broaden portfolio with complementary products that leverage current infrastructure
11
Building a leading US Women’s Health Business (BPD)
● Infrastructure in place
-
Experienced sales team of 100 (up from 86) able to reach our target customers
Refreshed team training initiative to improve sales productivity and impact
Full marketing mix to drive awareness and usage
Direct to Consumer (DTC) campaigns through traditional media campaigns, website and social media platforms
Able to leverage the coverage guarantees for contraception under the Affordable Care Act when fully enforced
● NEXTSTELLIS® has continued to achieve solid growth during 2H-FY23
-
Significant increase in call activity
>150% increase in samples distributed to HCPs, which is a leading indicator of new scripts
Direct-to-Consumer (DTC) campaign launch in 2023 driving 900% YoY increase in monthly consumer visitation to Nextstellis.com
Monthly cycle count increased to 26,596 in March 2023, up from 20,921 in December 2022, up 27%
March NRx up 20% over February, and Nextstellis Weekly Cycles now over 7,000
● Acquired Women's Health Branded Portfolio adding significant value
- Portfolio is delivering positive cash and earnings
- Investment in sales team and marketing spend in line with plan, paid search program commenced in April for ANNOVERA® and
-
menopause brands with encouraging web site visitation trends
Planned launch of lower strength BIJUVA® in 2HFY24 will attract new menopausal patients
Prenatal vitamins creating access to new customers
Q3-FY23 net sales exceeded, prior calendar Q4-2023 reported sales
NRx totals based on IQVIA Exponent Data adjusted for non-reporting pharmacies through 31Mar23
NRx totals based on IQVIA Rapid Weekly adjusted for non-reporting pharmacies through 28Apr23
12
NEXTSTELLIS® Website traffic increasing with DTC campaign
MONTHLY NEXTSTELLIS.COM U.S. USERS 2023 vs. 2022
200,000
214,000
Projected May website traffic
180,000
176,243
160,000
140,000
147,857
109,210
80,000
60,000
40,000
TV LAUNCH 13/2
120,000
100,000
173,419
48,487
20,000
-
January
February
March
April
May
June
2022
July
August
September
October
November
December
2023
● DTC investment July - November drove strong contribution to NRx and RRx (lower monthly DTC campaign investment in
December 2022 - January 2023 when NRx and RRx impact is reduced due to holidays)
● Changes made in Digital Media in December 2022 improving NRx and RRx attributed to DTC, expecting continued DTC NRx and
RRx lift in Q4 FY23 and Q1 FY24
13
May website data through May 7th – projections estimate full month volume
FY23 Q3 NEXTSTELLIS® Field Activity up dramatically over Q2
NRx totals based on IQVIA Exponent Data adjusted for non-reporting pharmacies through 31Mar23
14
Portfolio Products Division (PPD)
Portfolio Products Division (PPD)
Dermatology
● Revenue and contribution materially impacted by inventory
work through following 2HFY22 sales activities
- 1HFY23 Revenue of US$7.5m down 80% on 2HFY22 sales
of US$36.3m
- Direct contribution loss of US$-10.8m vs 2HFY22 of
US$4.4m.
- New market entrants affected key products
- Significant inventories in distribution channel led to sales
discounting and GTN adjustments to maintain customers
A$million
1H23
2H22
1H22
Reported revenue
59.1
125.6
118.6
Reported Gross Profit
(12.7)
26.5
52.6
Gross Profit %
-21%
21%
44.3%
Direct operating
expense1
20.5
17.5
15.4
Direct contribution
(33.2)
9.0
37.2
Portfolio Products revenue by type (US$m)
Retail generics
● 1HFY23 Revenue of US$32.2m down 36% on 2HFY22 sales of
US$54.8m
● Direct contribution loss of US$-6.4m vs 2H22 of US$5.6m
19%
US$40m
81%
● Continued competitive environment impacted performance
1. Direct marketing costs
16
Overview of the US Dermatology Market
Building market leadership and scale with pipeline of new products
Proprietary Brands
Specialty Partners
STRATEGIC PRIORITIES
✓ Build on strength of market position with strong, profitable pipeline of new products to meet broader patient needs
✓ Strengthen contribution margin through channel discipline and effective management of new launches and
appropriate channel supply agreements
✓ Maintain market presence as top 10 US products by revenue - gABSORICA® (isotretinoin) capsules, gEPIDUO® FORTE
(adapalene/benzoyl peroxide) gel and gACZONE® (dapsone) gel
✓ Execute our differentiated channel strategy through specialty pharmacy growth and online platforms like GoodRx
17
Dermatology – business performance improving; delivering on positive contribution margin
● Improving momentum following 1H-FY23 channel inventory issues which resulted in recalibration of pricing, GTN
and lower volumes in some products
● GTN and pricing has stabilised across key products, as expected
● We are actively managing each brand in our portfolio to maximise potential sustainable contribution margin
● We have returned to positive contribution margin during 3Q-FY23 as normal sales cadence resumes with
consistent sales volumes and stabilised pricing environment
● Seeing positive impact of new product launches – DORYX® MPC 60 in February and authorized gORACEA® in
March, which have been well received by the market
● Business remains focussed on further development of our differentiated channel strategy for patient access
which improves our attractiveness to dermatology partners
● We will continue to add new products to the portfolio that drive profitable growth
18
Dermatology Units growing and GTN stabilised
● Growth expected from Q3-FY23 launches
- DORYX® MPC 60 February 2023
- gORACEA® March 2023
● Gross sales increasing since August
● Net Sales growth since October
● GTN stabilised in Q3
19
International
International
● Good growth in international sales as product availability increases
following early improvement in manufacturing and supply chain
performance
● KAPANOL® /KADIAN® (morphine) market expansion to treat Opioid
Substitution Therapy (OST);
-
OST approved in Switzerland
-
Submitted in Austria
● KAPANOL® /KADIAN® (morphine) regional expansion for pain
indication in China
-
A$million
1H23
2H22
1H22
Reported revenue
27.6
26.8
27.6
Reported Gross Profit
8.9
8.8
8.8
Gross Profit %
33%
33%
32%
Direct operating
expense1
6.1
4.9
4.7
Direct contribution
2.8
3.9
4.1
Tripartite agreement signed and clinical trial application
submitted in China
● Australian dermatology portfolio extended through launch of
ACTIKERALL® (fluorouracil and salicylic acid for treatment of actinic
keratosis)
● Trading relationships and cadence with Dr Reddy's being
established with some sales expected later in current half
● NEXTSTELLIS® oral contraceptive launched in Australia, initial sales
behind plan due to execution of product messaging and sales force
commercial thrust which is being addressed as we did in the US
1. Direct marketing costs and general administration expenses including finance, HR and IT
10%
CDMO
A$27.6m
51%
Australian products
39%
International products
Share of International revenue by type 1H-FY23
21
International Improvement Initiatives
Manufacturing strategy focused on cost efficiency and reliable supply at the best quality
•
Organisational design review completed and implemented, focus on key roles in supply chain
•
Implementation of lean practices and metrics underway to unlock existing capacity and improve supply
reliability
•
Ongoing reduction of waste and deliberate focus on productivity
Focused revenue growth
•
Manufacturing improvements to enable capacity increase and cost efficiency underway
•
New business development capability implemented, engaged to secure both new local customers and
opening new market opportunities
•
Implementing best in class processes and metrics to drive efficient sales execution
Leveraging contract development and manufacturing as a differentiator and growth stream
•
Targeted focus on the right projects for capability and growth
22
Accelerating International Growth and Profitability
NEXTSTELLIS® launch in Australia
Federal Government grant to modernise Salisbury
● High Speed
Encapsulator
● High Speed Blister
Packing Line with
Serialisation
capabilities
Continue growth of Australian based CDMO business
● >10,000 interactions with healthcare providers since
launch in August 2022
● >10,000 samples distributed to physician offices
● Double digit CDMO
revenue growth vs 2HFY22
● Active promotion as a full
service CDMO with oral
solid dose and semi-solid
capabilities in ‘tier 1’
markets
23
Outlook
Strategic priorities for FY23 & FY24 to drive shareholder value
# 1 Priority, B/E ASAP
Deliver EBITDA Positive WH
Successfully
Successfully
Deliver on the full
commercialise
implement
new
Women’s Health
NEXTSTELLIS® in
commercial
franchise
the
strategy
forUS and
ANNOVERA®
Australia
NEXTSTELLIS®
to
BIJUVA®
accelerate growth
IMVEXXY®
in the US and
NEXTSTELLIS®
Australia
Pre-Natal Vitamins
Improve Margin & Access
Secure accretive assets
Accelerate AU Growth
US channel
strategy to
improve margins
in dermatology
and women’s
health and
provide better
patient access
Broaden portfolio
with
complementary
products that
leverage existing
commercial
infrastructure in
dermatology and
women’s health
Continued
profitable growth
of Australian based
specialty
pharmaceutical,
International sales
and CDMO
business
25
Outlook
● FY23 has been one of significant business transition with the completion of the sale of MCS and Retail Generics and the
acquisition of the TXMD portfolio
● Momentum continues to build across BPD/Women’s Health portfolio following acquisition and investment in new products as
well as our sales and marketing capability to support our contraception, menopause, and specialty brands
- Anticipated timing for NEXTSTELLIS® to achieve its breakeven weekly run rate is now in 1H24
- Performance of the whole portfolio is delivering steady revenue growth and positive contribution in 2H23 with the
acquired assets more than offsetting NEXTSTELLIS® investments for growth
● Following stabilisation, Dermatology has now returned to delivering positive net revenue and contribution margin
- Momentum is anticipated to continue through the remainder of the half, supported by the recent product launches
● Our operational excellence plan implemented for the International business will take time to gain traction
- Relatively flat performance is expected in 2H23
● Overall, the continuing businesses are expected to deliver positive revenue and contribution margin in 2H23 vs 1H23
- Return to Group profitability in FY24, even with stranded costs from the RGx business and the time required for changes
made to NEXTSTELLIS® to deliver on top line growth
● We expect FY23 underlying EBITDA to be aligned with the consensus of the two analysts covering Mayne Pharma
26
Q&A
You deserve tomorrow.
27
Share your feedback
Discover